This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal squamous cell carcinoma (ESCC). The primary research objectives are to increase the R0 resection rate in such patients, thereby reducing the recurrence rate and improving overall survival (OS), as well as avoiding adverse reactions associated with radiotherapy.
None
Patients with cervical esophageal squamous cell carcinoma.
Patients with distant metastasis.
Patients with nearly complete esophageal obstruction confirmed by endoscopy who require interventional therapy for decompression.
Patients with prior placement of esophageal or tracheal stents.
Single group
Adebrelimab Injection
DrugStudy participants shall complete the informed consent process and undergo multidisciplinary team (MDT) review for esophageal cancer. Patients confirmed as having borderline resectable disease and meeting all inclusion/exclusion criteria will be enrolled and receive treatment with adebrelimab plus albumin-bound paclitaxel and carboplatin.The treatment regimen is administered in 3-week cycles. Efficacy evaluation will be performed after 2 cycles.
R0 resection rate
The proportion of patients with tumor margins showing no residual cancer cells under the microscope after surgical resection. That is, the proportion of patients in PPS achieving R0 resection.
Overall survival
OS is the time interval from the start of treatment to death due to any reason or loss of follow-up
Progression free survival
Disease free survival (DFS) refers to the time from the start of treatment until disease recurrence or death from any cause, whichever occurs first.
Pathologic complete response rate
Incidence of perioperative complications
Click on the lead sponsor to view all of their trials.
